Literature DB >> 31951559

One or Two Immune Checkpoint Inhibitors?

Caroline Robert1, Emilie Lanoy2, Benjamin Besse3.   

Abstract

The combination of ipilimumab and nivolumab was evaluated versus standard treatments in melanoma and lung cancer. Analysis of these trials highlights the differences in outcomes and potential predictive biomarkers across tumor types as well as the multiple remaining questions concerning the optimal use of immune checkpoint inhibitors.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31951559     DOI： 10.1016/j.ccell.2019.11.005

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  7 in total

1.  Blocking Migration of Polymorphonuclear Myeloid-Derived Suppressor Cells Inhibits Mouse Melanoma Progression.

Authors:  Christopher Groth; Ludovica Arpinati; Merav E Shaul; Nina Winkler; Klara Diester; Nicolas Gengenbacher; Rebekka Weber; Ihor Arkhypov; Samantha Lasser; Vera Petrova; Hellmut G Augustin; Peter Altevogt; Jochen Utikal; Zvi G Fridlender; Viktor Umansky
Journal:  Cancers (Basel)       Date:  2021-02-10       Impact factor: 6.639

2.  Immune Checkpoint Inhibitor Therapy Aggravates T Cell-Driven Plaque Inflammation in Atherosclerosis.

Authors:  Kikkie Poels; Mandy M T van Leent; Celine Boutros; Hubert Tissot; Séverine Roy; Anu E Meerwaldt; Yohana C A Toner; Myrthe E Reiche; Pascal J H Kusters; Tsveta Malinova; Stephan Huveneers; Audrey E Kaufman; Venkatesh Mani; Zahi A Fayad; Menno P J de Winther; Aurelien Marabelle; Willem J M Mulder; Caroline Robert; Tom T P Seijkens; Esther Lutgens
Journal:  JACC CardioOncol       Date:  2020-10-06

3.  Validation of an online application to identify potential immune-related adverse events associated with immune checkpoint inhibitors based on the patient's symptoms.

Authors:  Takahiro Osawa; Takashige Abe; Hiroshi Kikuchi; Ryuji Matsumoto; Sachiyo Murai; Takafumi Nakao; Shinji Tanaka; Ayu Watanabe; Nobuo Shinohara
Journal:  PLoS One       Date:  2022-03-15       Impact factor: 3.240

Review 4.  Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons.

Authors:  Adel Naimi; Rebar N Mohammed; Ahmed Raji; Supat Chupradit; Alexei Valerievich Yumashev; Wanich Suksatan; Mohammed Nader Shalaby; Lakshmi Thangavelu; Siavash Kamrava; Navid Shomali; Armin D Sohrabi; Ali Adili; Ali Noroozi-Aghideh; Ehsan Razeghian
Journal:  Cell Commun Signal       Date:  2022-04-07       Impact factor: 5.712

5.  Homologous recombination repair gene mutations as a predictive biomarker for immunotherapy in patients with advanced melanoma.

Authors:  Zhixuan You; Meng Lv; Xuanyu He; Yingqin Pan; Junfeng Ge; Xue Hu; Yating Zheng; Mengli Huang; Chengzhi Zhou; Changxuan You
Journal:  Front Immunol       Date:  2022-08-03       Impact factor: 8.786

6.  The Predictive Value of MAP2K1/2 Mutations on Efficiency of Immunotherapy in Melanoma.

Authors:  Ting Ye; Jie-Ying Zhang; Xin-Yi Liu; Yu-Han Zhou; Si-Yue Yuan; Meng-Mei Yang; Wen-Zhuan Xie; Chan Gao; Yao-Xu Chen; Meng-Li Huang; Cheng-Zhi Ye; Jing Chen
Journal:  Front Immunol       Date:  2022-01-06       Impact factor: 7.561

Review 7.  Chemokines in the Landscape of Cancer Immunotherapy: How They and Their Receptors Can Be Used to Turn Cold Tumors into Hot Ones?

Authors:  Nathan Karin
Journal:  Cancers (Basel)       Date:  2021-12-16       Impact factor: 6.639
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.